Table 1. . Included chemotherapy regimens, with coupled outcome variables.
| Chemotherapy | Outcome | Arms | Minimum | Lower quartile | Median | Upper quartile | Maximum | Ref. |
|---|---|---|---|---|---|---|---|---|
| 5-FU | OS | 10 | 4.6 | 5.1 | 7.7 | 9.0 | 14.8 | [8,13–21] |
| ADDIN EN.CITE | PFS | 9 | 1.0 | 3.3 | 3.7 | 4.0 | 4.7 | |
| RR | 9 | 0.0 | 7.0 | 14.3 | 32.0 | 35.0 | ||
| 5-FU + platinum | OS | 13 | 3.1 | 8.0 | 9.5 | 10.0 | 12.8 | [13,22–31] |
| ADDIN EN.CITE | PFS | 11 | 1.4 | 3.3 | 3.7 | 4.8 | 6.5 | |
| RR | 13 | 0.0 | 19.0 | 21.4 | 30.0 | 42.9 | ||
| ECF | OS | 6 | 4.9 | 5.8 | 8.5 | 9.1 | 9.9 | [32–37] |
| ADDIN EN.CITE | PFS | 5 | 1.9 | 4.6 | 5.1 | 5.2 | 5.6 | |
| RR | 6 | 10.0 | 10.0 | 19.1 | 22.5 | 40.0 | ||
| Gemcitabine | OS | 10 | 5.8 | 7.5 | 8.4 | 11.5 | 14.0 | [10,38–46] |
| ADDIN EN.CITE | PFS | 9 | 2.5 | 2.6 | 4.3 | 5.6 | 8.1 | |
| RR | 9 | 0.0 | 9.4 | 17.5 | 26.1 | 36.0 | ||
| Gemcitabine+platinum | OS | 24 | 5.0 | 8.7 | 9.5 | 10.8 | 19.9 | [8,10,22,47–66] |
| ADDIN EN.CITE | PFS | 23 | 3.0 | 4.0 | 4.8 | 7.8 | 11.0 | |
| RR | 21 | 14.9 | 21.0 | 29.0 | 32.0 | 50.0 | ||
| Gemcitabine + 5-FU | OS | 17 | 4.7 | 8.9 | 12.5 | 14.0 | 16.0 | [20,38,67–81] |
| ADDIN EN.CITE | PFS | 14 | 2.9 | 4.6 | 6.1 | 7.1 | 9.0 | |
| RR | 15 | 9.5 | 21.4 | 30.0 | 31.4 | 38.0 | ||
| Gemcitabine + 5-FU + platinum | OS | 2 | 9.9 | 9.9 | 10.0 | 10.0 | 10.0 | [82] |
| ADDIN EN.CITE | PFS | 0 | – | – | – | – | – | |
| RR | 2 | 19.0 | 19.0 | 21.0 | 23.0 | 23.0 | ||
| Gemcitabine + pemetrexed | OS | 1 | 6.6 | 6.6 | 6.6 | 6.6 | 6.6 | [83] |
| PFS | 1 | 3.8 | 3.8 | 3.8 | 3.8 | 3.8 | ||
| RR | 1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | ||
| 5-FU+etoposide + leucovorin | OS | 1 | 12.0 | 12.0 | 12.0 | 12.0 | 12.0 | [34] |
| PFS | 1 | 7.8 | 7.8 | 7.8 | 7.8 | 7.8 | ||
| RR | 1 | 15.0 | 15.0 | 15.0 | 15.0 | 15.0 | ||
| Gemcitabine + irinotecan | OS | 1 | 7.6 | 7.6 | 7.6 | 7.6 | 7.6 | [84] |
| PFS | 1 | 4.3 | 4.3 | 4.3 | 4.3 | 4.3 | ||
| RR | 1 | 20.5 | 20.5 | 20.5 | 20.5 | 20.5 | ||
| Oxaliplatin + irinotecan | OS | 1 | 9.2 | 9.2 | 9.2 | 9.2 | 9.2 | [85] |
| PFS | 1 | 2.7 | 2.7 | 2.7 | 2.7 | 2.7 | ||
| RR | 1 | 17.9 | 17.9 | 17.9 | 17.9 | 17.9 | ||
| Irinotecan + 5-FU | OS | 1 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | [86] |
| PFS | 1 | 4.0 | 4.0 | 4.0 | 4.0 | 4.0 | ||
| RR | 1 | 10.0 | 10.0 | 10.0 | 10.0 | 10.0 | ||
5-FU: 5-fluorouracil; ECF: Epirubicin, cisplatin and 5-FU; OS: Overall survival; PFS: Progression-free survival; RR: Response rate.